Evidence map›Paper›PMID 29980224›Full record

Trial reportHealth and quality of life outcomes2018

Effect of low-normal and high-normal IGF-1 levels on memory and wellbeing during growth hormone replacement therapy: a randomized clinical trial in adult growth hormone deficiency.

Christa C van Bunderen, Jan Berend Deijen, Madeleine L Drent

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Health and quality of life outcomes, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01877512 (Effect of Growth Hormone Replacement Therapy on Cardiovascular Risk Factors in Adult Patients With Severe Growth Hormone Deficiency), which is not on this map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01877512 phase4completednot on this map

Effect of Growth Hormone Replacement Therapy on Cardiovascular Risk Factors in Adult Patients With Severe Growth Hormone Deficiency: Association With IGF-I Concentration

TypeinterventionalSponsorAmsterdam UMC, location VUmcRan2013 to 2014Enrolled32ConditionsGrowth Hormone Deficiency, Cardiovascular Diseases, Metabolic Syndrome, CognitionArmsChange in daily dosage of Growth Hormone
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Article
  8. Role of bisphosphonates in osteoporosis caused by adult growth hormone deficiency.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Christa C van BunderenDepartment of Internal Medicine, section of Endocrinology, Neuroscience Campus Amsterdam, VU University Medical Center, De Boelelaan 1117, 1081, HV, Amsterdam, the Netherlands. c.vanbunderen@vumc.nl.ORCID http://orcid.org/0000-0003-0006-7726
Jan Berend DeijenDepartment of Clinical Neuropsychology, VU University, Amsterdam, the Netherlands.
Madeleine L DrentDepartment of Internal Medicine, section of Endocrinology, Neuroscience Campus Amsterdam, VU University Medical Center, De Boelelaan 1117, 1081, HV, Amsterdam, the Netherlands.
Amsterdam Neuroscience · NL

Funding

ZonMw 92003591
6 · The paper itself

Abstract

backgroundThe aim of the present study was to investigate the effect of low-normal and high-normal levels of IGF-1 in growth hormone (GH) deficient adults on cognition and wellbeing during GH treatment.

methodsA randomized, open-label, clinical trial including 32 subjects receiving GH therapy for at least 1 year. Subjects were randomized to receive either a decrease (IGF-1 target level of - 2 to - 1 SDS) or an increase of their daily GH dose (IGF-1 target level of 1 to 2 SDS) for a period of 24 weeks. Memory was measured by the Cambridge Neuropsychological Test Automated Battery, selecting the Pattern Recognition Memory task and the Spatial Working Memory. Wellbeing was measured as mood by the Profile of Moods States questionnaire, and quality of life by the Nottingham Health Profile and QoL Assessment in GH Deficiency in Adults questionnaires.

resultsData from 30 subjects (65.6% male, mean age 46.6 (9.9 SD) years), who fulfilled the target levels, were analyzed. Females in the low dose treatment arm were found to have a better working memory and a better strategic memory control after 24 weeks as opposed to the females in the high treatment arm. With respect to mood, the decrease in IGF-1 levels in females within the low treatment arm was associated with more fatigue and less vigor.

conclusionsThe adjustment of GH dose in female patients seems to have a narrow window. A dose too high may impair prefrontal cognitive functioning, while a dose too low may result in decreased vigor.

trial registrationThis study is registered with ClinicalTrials.gov , number NCT01877512.

Indexed as

Quality of LifeAdultAffectCognitionFemaleGrowth DisordersHormone Replacement TherapyHuman Growth HormoneHumansInsulin-Like Growth Factor IMaleMemoryMiddle AgedSex FactorsHuman Growth HormoneIGF1 protein, humanInsulin-Like Growth Factor ICognitionGrowth hormone deficiencyGrowth hormone treatmentInsulin-like growth factor-1MemoryMood

Identifiers

PMID29980224
PMCPMC6035403
OpenAlexW2862562132

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.